Prograf Articles
Prograf turned down for bone marrow transplants
13 January 1999
Stock Commentary Tokyo
3 December 1998
Fujisawa Reports Steady Interim Growth
11 November 1998
Fujisawa Fights Back In Shrinking Domestic Market
15 September 1998
Fujisawa Expanding Prograf Facility
9 September 1998
Fujisawa Market Prograf In Mexico And Taiwan
3 September 1998
Stock Commentary Tokyo
30 July 1998
AHP's Rapamune Improves 6-Month Graft Survival
16 July 1998
Fujisawa Invests $10 Million In ABS
15 June 1998
Net Loss Plunges To $270 Million At Fujisawa
21 May 1998
Fujisawa Restructuring In The USA, Revises Forecasts
31 March 1998
Stock Commentary Tokyo
19 February 1998
Takeda, Diabetes Drive Japanese Blockbusters
19 February 1998
Fujisawa To Expand Prograf Marketing
29 January 1998
Dade Behring In Sublicense Deal With Abbott
22 January 1998
Fujisawa Says Global Business Growing Steadily
4 December 1997
Mixed Results From Japanese Drugmakers
12 November 1997
1st Half Decrease in Sales At Fujisawa
10 November 1997
Stock Commentary Tokyo
7 November 1997
UK Industry Code Of Practice Report
1 September 1997
Japanese Plan Export Boost To Beat NHI Price Curbs
1 August 1997
Fujisawa Sees 31% Net Income Rise For FY1996
26 May 1997
FDA Approves Fujisawa's Prograf
12 May 1997
Sequus Amphotec Launched In USA
16 December 1996
New Nerve Repair Drug From Vertex
25 November 1996
Nonconsolidated Interims From Fujisawa
11 November 1996
Fujisawa To Launch Prograf In Spain
2 September 1996
UK Medicines Control Agency Report For 1995-96
19 August 1996
Prograf Approved In Japan For Kidney Transplant
29 April 1996
Ireland: New Foreign Investments In 1995
19 February 1996
Prograf Approved In Canada
12 February 1996
Prix Galien For Roche And Glaxo Wellcome
29 January 1996
Tokyo Stock Comment
4 December 1995
Fujisama's Prograf in atopic dematitis
27 November 1995
Japan's Fujisawa Looks To 21 Century Growth
16 October 1995
Tokyo stock comment
24 July 1995
Fujisawa Sets Up New FK-506 Facility
17 July 1995
J&J Licenses Prograf In Australia, NZ
12 June 1995
Fujisawa Net Down Though Operating Income Soars
29 May 1995
Phase IV studies of Prograf
15 May 1995
Prograf Linked To Cardiotoxicity?
17 April 1995
FDA Panel Backs Cellcept For Acute Rejection
10 April 1995
Second European Launch For Prograf
10 April 1995
TOKYO STOCK COMMENT
2 January 1995
TOKYO STOCK COMMENT
14 November 1994
Fujisawa Launches Prograf In The UK
31 October 1994
Historic Fiscal YearFor Fujisawa
24 October 1994
FK506 TO PREVENT BRAIN CELL DEATH
3 October 1994
Fujisawa Wins Back Rights In USA
19 September 1994
New Drug Developments In Transplant Medicine
12 September 1994
Tacrolimus More Effective Than Cyclosporin
22 August 1994
Vertex Predicts Four Drugs In Trials By End-1994
25 July 1994
SANDIMMUN SET FOR DECLINE, SAYS ANALYST
27 June 1994
FUJISAWA'S PROGRAF APPROVED FOR LIVER TRANSPLANTS IN USA
18 April 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
1993 A GRIM YEAR FOR INDUSTRY, SAYS SANOFI
6 December 1993
FDA PANEL BACKS FUJISAWA'S PROGRAF
6 December 1993
PROGRAF TRIALS BEGIN IN UK
29 November 1993
FUJISAWA NET INCOME DOWN 44.9% AT INTERIM
15 November 1993
FUJISAWA FILES NDA FOR PROGRAF
13 September 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
EUROPE STOCK COMMENT
7 June 1993
FIRST LAUNCH OF FUJISAWA'S PROGRAF
7 June 1993
NET INCOME FALLS 77% IN 1992 AT FUJISAWA
31 May 1993
TOKYO STOCK COMMENT
29 March 1993
PROGRAF HEADS NEW JAPANESE APPROVALS
22 March 1993
FUJISAWA'S PROMISING R&D PIPELINE
9 November 1992
ANTI-CD3 POTENTIAL DIABETES TREATMENT
12 October 1992
FUJISAWA HIT BY JAPAN DRUG PRICING MOVES
1 June 1992
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
